CLL
From the Journals
Adding umbralisib to ibrutinib produced responses in MCL, CLL
The doublet regimen “is the first successful combination for two drugs targeting B-cell blockade.”
Feature
MD Anderson–led alliance seeks to advance leukemia drug development
The research collaboration will focus on novel therapies for AML, CML, ALL, myeloproliferative neoplasms, and myelofibrosis.
Conference Coverage
Armored CAR protects T cells, induces remissions
SAN DIEGO – A CAR T-cell construct engineered to enhance T-cell persistence and immune function induced high complete remission rates in a phase 1...
Conference Coverage
Long-term side effects of CAR T cells mostly mild
SAN DIEGO – Follow-up of patients who survived at least 1 year after CAR T-cell infusions suggests that the technology is safe.
Conference Coverage
CLL at ASH: A ‘mountain of data’ for targeted therapies
SAN DIEGO – Dr. Brian Hill and Dr. Anthony Mato break down the take-home points from the key studies on chronic lymphocytic leukemia presented at...
Conference Coverage
Ibrutinib-rituximab ‘new standard of care’ in younger CLL patients
SAN DIEGO – Survival and safety outcomes were better with ibrutinib and rituximab than with the FCR regimen.
Conference Coverage
2018: A banner year for hematology drug approvals
SAN DIEGO – There have been 32 new hematology drug approvals and the year isn’t over yet.
News
CLL resistance mechanism to venetoclax identified
SAN DIEGO – The mutation was present only after therapy in paired samples from patients enrolled in clinical trials of venetoclax.
Conference Coverage
Ibrutinib outperforms bendamustine and rituximab in older CLL patients
SAN DIEGO – Ibrutinib, which is now widely used in older CLL patients, provided better progression-free survival than bendamustine and rituximab...
From the Journals
Cortactin expression aids in CLL-MCL differential
Cortactin, a cytoskeleton-remodeling adapter protein, is expressed on most CLL cells, but not similar-appearing MCL cells.
Conference Coverage
ASH 2018 coming attractions look at the big picture
Big trials, big results in malignant and nonmalignant hematologic disorders are on the program at the 2018 ASH annual meeting.